PeptideScouterPeptideScouterIndex

Peptide Price Index, September 2026: GLP-1s Led the Cuts

· Price Index

This is the fifth issue of a monthly index of listed research peptide prices, following the May, June, July and August issues.

September's cuts went to one corner of the market. Listings of tirzepatide, retatrutide and semaglutide were cut three times as often as everything else, led by one vendor that took a quarter off its whole GLP-1 line in a single day. The rest of the market was quieter than in August: 85% of tracked listings ended the month at the price they started it, and the median compound did not move.

What was measured

Prices are compared listing against listing, between the first week of September and the last. A listing counts only if it was in stock and priced in both.

Full definitions are on the methodology page.

Prices stayed sticky for a fifth month

Of the 1,162 listings, 990 (85%) ended September at exactly the price they started it. That is the fifth consecutive month in the same band: 78% in May, 88% in June, 76% in July, 83% in August, 85% in September.

Among the 172 listings that did move, 146 fell and 26 rose, and the median mover fell 11.1%.

As of September 30, 2026, the median listed price across the compounds in the index was $4.80 per milligram. That is ten cents below August's figure, but the difference comes from what the index covers rather than from prices: it tracked 33 vendors at the end of September against 23 at the end of August, and on the listings tracked at both month-ends the median compound's price did not change. Half of all listings fell between $2.77 and $7.00 per milligram.

Fourteen of the 24 vendors in the panel ended September with every tracked price exactly where it began, up from 11 of 21 in August.

The cuts landed on GLP-1 agonists

Of the 227 tracked listings of tirzepatide, retatrutide and semaglutide, 62 fell in September, or 27%. Across everything else in the index, 84 of 935 listings fell, or 9%. Only seven of the 227 rose.

EZ Peptides accounts for about a third of the index's net decline for the month. No vendor carried September the way Peptide Giants carried August: having cut 71 listings in August, it changed one in September.

One catalog-wide cut, two sales and one increase

The largest single increase was SS-31 at Ascension Peptides, up 33% from $6.00 to $8.00 per milligram. The largest decrease was sermorelin at HLX Labs, down 50% from $12.00 to $6.00 per milligram on a 5 mg vial.

The gap between vendors held steady

Among compounds carried by five or more vendors, the median one costs about five times as much at its dearest listing as at its cheapest, as of September 30, 2026. That is wider than the three to four times reported for August because the index now covers more vendors, which puts more listings at both extremes. Among vendors tracked at both month-ends, the gap narrowed for nine compounds, widened for eight and did not change for 22.

These are the widest, as of September 30, 2026.

Still no price response to the FDA vote

Ten weeks after FDA's Pharmacy Compounding Advisory Committee recommended six of seven peptides for the 503A compounding list, the five measurable recommended peptides again repriced no more often than the rest of the market: 15% of their 150 tracked listings changed price in September, against 15% of everything else, and the median change was zero in both. The four-week reading found the same.

FDA has not opened rulemaking on the list. As of October 1, 2026, the Federal Register carries no FDA document on the 503A bulk drug substances list since the meeting.

What this does not measure

Sources

All figures in this report are as of September 30, 2026, computed from the archive as of publication.

Suggested citation: PeptideScouter. Peptide Price Index, September 2026. https://peptidescouter.com/blog/peptide-price-index-september-2026 (figures as of Wednesday, September 30, 2026). Data: doi:10.5281/zenodo.23091032.

PeptideScouter indexes vendor prices for research chemicals sold for laboratory use only, not for human consumption. Nothing here is medical, legal, or investment advice. We earn affiliate commissions on some outbound vendor links - see our disclosure.